Jan Willem de Groot

1.8k citations

55 papers · 629 indexed · h-index 12

Oncology top 10%
- Colorectal Cancer Treatments and Studies 16
- Cancer Immunotherapy and Biomarkers 13
- Cutaneous Melanoma Detection and Management 9
- Cancer Treatment and Pharmacology 8
- CAR-T cell therapy research 7
Immunology
- Immunotherapy and Immune Responses 6
Hepatology
Pulmonary and Respiratory Medicine
- Gastric Cancer Management and Outcomes 5
Cancer Research
Molecular Biology
- Melanoma and MAPK Pathways 18

Co-authors: Christian U. Blank Martijn H. den Brok I. Jolanda M. de Vries Rutger H.T. Koornstra Niven Mehra Sandra van Wilpe Winald R. Gerritsen Willem Den Otter
Cited by: Oncology Immunology Hepatology
Journals: Journal of Clinical Oncology (20 papers)Annals of Oncology (14 papers)International Journal of Cancer (2 papers)
Partner nations: Netherlands United States Germany

In The Last Decade

Jan Willem de Groot

51 papers receiving 614 citations

Peers

Countries citing papers authored by Jan Willem de Groot

Since Specialization

Citations

This map shows the geographic impact of Jan Willem de Groot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Willem de Groot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Willem de Groot more than expected).

Fields of papers citing papers by Jan Willem de Groot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Willem de Groot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Willem de Groot. The network helps show where Jan Willem de Groot may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jan Willem de Groot, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jan Willem de Groot Line = papers co-authored together Jan Willem de Groot links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	36P Interpretable histomorphological subtypes linked to ICI response in advanced melanoma using AI-assisted histopathology analysis TU/e Research Portal ·Mark Schuiveling,I. van Duin,Laurens S. ter Maat,Jaap van der Weerd,F. Van den Berkmortel,F. Burgers,M. Boers-Sonderen,M. Labots,Jan Willem de Groot,J.B.A.G. Haanen,Geke A.P. Hospers,E. Kapiteijn,Djura Piersma,Lieke H. J. Simkens,Hans M. Westgeest,Paul van Diest,Josien P. W. Pluim,K. Suijkerbuijk,Willeke A.M. Blokx,Mitko Veta	2025	0
2	LBA57 Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma Annals of Oncology ·M.W. Lucas,A.M. Menzies,P. Dimitriadis,S C M A Wijnen,Marta López‐Yurda,Richard A. Scolyer,B. van de Wiel,Robyn P.M. Saw,A. Kuijpers,A. Torres Acosta,Joyce Sanders,M.S. Carlino,Jan Willem de Groot,E. Kapiteijn,K. Suijkerbuijk,P. Rutkowski,Shahneen Sandhu,Astrid A.M. van der Veldt,G.V. Long,C.U. Blank	2025	0
3	LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial Annals of Oncology ·M.W. Lucas,A.M. Menzies,Marta López‐Yurda,Richard A. Scolyer,B. van de Wiel,R.P.M. Saw,W. Van Houdt,Nigel G. Maher,A. Torres Acosta,M. Boers-Sonderen,G. Hospers,M.S. Carlino,Jan Willem de Groot,E. Kapiteijn,K. Suijkerbuijk,P. Rutkowski,Shahneen Sandhu,Astrid A.M. van der Veldt,G.V. Long,C.U. Blank	2024	6
4	Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score–matched recurrence-free, distant metastasis-free, and overall survival analysis. Journal of Clinical Oncology ·Manja Bloem,Melissa M. de Meza,Maureen J.B. Aarts,Franchette van den Berkmortel,Christian U. Blank,Willeke A.M. Blokx,Marye J. Boers‐Sonderen,Han J. Bonenkamp,Jan Willem de Groot,John B.A.G. Haanen,Geke A.P. Hospers,Ellen Kapiteijn,Djura Piersma,Rozemarijn van Rijn,Marion Stevense - den Boer,Astrid Aplonia Maria Van Der Veldt,Gerard Vreugdenhil,Alfonsus Johannes Maria van den Eertwegh,Karijn P.M. Suijkerbuijk,Michel W.J.M. Wouters	2024	1
5	Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. Journal of Clinical Oncology ·Christian U. Blank,Minke W. Lucas,Richard A. Scolyer,Bart A. van de Wiel,Alexander M. Menzies,Marta López‐Yurda,Alexander Christopher Jonathan Van Akkooi,Winan J. van Houdt,Robyn P.M. Saw,Alex Torres Acosta,Serigne Lo,Geke A.P. Hospers,Matteo S. Carlino,Jan Willem de Groot,Ellen Kapiteijn,Karijn P.M. Suijkerbuijk,Piotr Rutkowski,Shahneen Sandhu,Astrid Aplonia Maria Van Der Veldt,Georgina V. Long	2024	9
6	Primary outcome analysis of the ORCHESTRA trial: A randomized phase III trial of additional tumor debulking to first-line palliative systemic therapy for patients with multiorgan metastatic colorectal cancer. Journal of Clinical Oncology ·Elske C. Gootjes,Anviti A. Adhin,Lotte Bakkerus,Barbara M. Zonderhuis,Kathelijn S. Versteeg,Jurriaan B. Tuynman,Martijn R. Meijerink,Cornelis J.A. Haasbeek,Johannes H.W. de Wilt,Dirk J. Grünhagen,Ewoud J. Smit,John Primrose,John Bridgewater,Esther van Meerten,Jan Willem de Groot,Mathijs P. Hendriks,Esther Oomen‐de Hoop,Tineke E. Buffart,Henk M.W. Verheul,Cornelis Verhoef	2024	9
7	1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma Annals of Oncology ·Dirk Schadendorf,Reinhard Dummer,K. T. Flaherty,Caroline Robert,Ana Arance,Jan Willem de Groot,Claus Garbe,Helen Gogas,Ralf Gutzmer,Ivana Krajsová,Gabriella Liszkay,Carmen Loquai,Mario Mandalà,Naoya Yamazaki,Carolin Guenzel,Anna Polli,M. Thakur,Alessandra di Pietro,Paolo A. Ascierto	2023	3
8	602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma Annals of Oncology ·Andrew Haydon,Dirk Schadendorf,Reinhard Dummer,K. T. Flaherty,Caroline Robert,Ana Arance,Jan Willem de Groot,Claus Garbe,Helen Gogas,Ralf Gutzmer,Ivana Krajsová,Gabriella Liszkay,Carmen Loquai,Mario Mandalà,Naoya Yamazaki,Carolin Guenzel,Anna Polli,M. Thakur,Alessandra di Pietro,Paolo A. Ascierto	2023	2
9	1112P Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial Annals of Oncology ·Lianne Hoeijmakers,E.A. Rozeman,Marta López‐Yurda,Lindsay G. Grijpink-Ongering,Birthe C. Heeres,B. van de Wiel,Claudie C. Flohil,Ayşegül Sarı,Stijn W. T. P. J. Heijmink,Daan van den Broek,Annegien Broeks,Jan Willem de Groot,Marieke A. Vollebergh,Sofie Wilgenhof,H.V. van Thienen,John B.A.G. Haanen,Christian U. Blank	2023	1
10	LBA27 First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group Annals of Oncology ·Cornelis J.A. Punt,Marinde J. G. Bond,Karen Bolhuis,O. J. L. Loosveld,Jan Willem de Groot,Helga Droogendijk,Helgi H. Helgason,Mathijs P. Hendriks,Joost M. Klaase,Geert Kazemier,Mike S.L. Liem,Arjen M. Rijken,Cornelis Verhoef,Johannes H. W. de Wilt,Koert P. de Jong,M.J. van Amerongen,B. De Valk,Emile D. Kerver,Aysun Komurcu,R-J. Swijnenburg	2023	4
11	1092P Adjuvant treatment with anti-PD-1 in acral melanoma patients: A nationwide study Annals of Oncology ·Martin W. Bloem,Olivier J. van Not,J.B.A.G. Haanen,C.U. Blank,Maureen J.B. Aarts,Franchette W.P.J. van den Berkmortel,Jan Willem de Groot,Geke A.P. Hospers,Ellen Kapiteijn,Djura Piersma,R.S. van Rijn,M. Stevense-den Boer,Astrid A.M. van der Veldt,Gerard Vreugdenhil,Han J. Bonenkamp,M. J. Boers‐Sonderen,Willeke A.M. Blokx,F. Van Den Eertwegh,Karijn P.M. Suijkerbuijk,Michel W.J.M. Wouters	2023	0
12	Pandemic ICU triage challenge and medical ethics BMJ Supportive & Palliative Care ·Sabine Netters,Nick Dekker,Koos van de Wetering,Annie J. Hasker,Dian Paasman,Jan Willem de Groot,Kris Vissers	2021	18
13	Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study European Journal of Cancer ·Michel Ducreux,Lone Nørgård Pétersen,Leopold Öhler,Francesca Bergamo,Jean‐Philippe Metges,Jan Willem de Groot,Jaw‐Yuan Wang,Beatriz Paredes,Emmanuelle Dochy,Sabine Fiala-Buskies,Andrés Cervantes,Juan Manuel O’Connor,Alfredo Falcone	2019	44
14	The association between sarcopenic overweight and chemotherapy toxicity in Bile Duct and Gallbladder cancer patients treated with Gemcitabine and Cisplatin HPB ·Marcia P. Gaspersz,Ali Belkouz,Joeri Dierks,Jan Willem de Groot,Marjolein Rentinck,C. Yung Nio,Bas Groot Koerkamp,Heinz‐Josef Klümpen,Jan N.M. IJzermans,J. van Vugt	2018	1
15	Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands International Journal of Clinical Oncology ·Johannes J.M. Kwakman,Geraldine R. Vink,J.H.M.J. Vestjens,Laurens V. Beerepoot,Jan Willem de Groot,Slinger Jansen,Frans L. Opdam,Henk Boot,G.J. Creemers,Johan M. van Rooijen,Maartje Los,A. J. E. Vulink,Heidi Schut,E. van Meerten,Arnold Baars,Paul Hamberg,Ellen Kapiteijn,Dirkje W. Sommeijer,Cornelis J.A. Punt,Miriam Koopman	2017	27
16	A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients Annals of Oncology ·Judith Honing,Justin K. Smit,Christina T. Muijs,Johannes G. M. Burgerhof,Jan Willem de Groot,Gabriel Paardekooper,Karin Müller,D. Woutersen,Marie-Cecile Legdeur,W. Edward Fiets,Annerie Slot,Jannet C. Beukema,John Th. M. Plukker,Geke A.P. Hospers	2014	87
17	Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation Endocrine Related Cancer ·Ruxandra‐Iulia Milos,Karin Frank‐Raue,Nelson Wohllk,Ana Luiza Maia,Eduardo Pusiol,Attila Patócs,Mercedes Robledo,Josefina Biarnés,Marta Barontini,Th. P. Links,Jan Willem de Groot,Šárka Dvořáková,Mariola Pęczkowska,Lisa Rybicki,Mackenzie W. Sullivan,F. Raue,Ioana Zosin,Charis Eng,Hartmut P.H. Neumann	2008	38
18	Optimal regimes for local IL-2 tumour therapy International Journal of Cancer ·Willem Den Otter,Jan Willem de Groot,Monique R. Bernsen,A. Peter M. Heintz,Riks Maas,Gerrit Jan Hordijk,F.W. Hill,Wim R. Klein,E. J. Ruitenberg,Victor P. M. G. Rutten	1996	25
19	Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice Cancer Immunology Immunotherapy ·Joep J. Bergers,Willem Den Otter,Hub F. J. Dullens,Jan Willem de Groot,Peter A. Steerenberg,Monique W. H. Mimpen,Daan J.A. Crommelin	1993	7
20	Differences in the Induction of Macrophage Cytotoxicity by the Specific T Lymphocyte Factor, Specific Macrophage Arming Factor (SMAF), and the Lymphokine, Macrophage Arming Factor (SMAF), and the Lymphokine, Macrophage Activating Factor (MAF) Immunobiology ·Jan Willem de Groot,R.A. De Weger,Rob J. Vandebriel,Willem Den Otter	1989	8

About Jan Willem de Groot

Jan Willem de Groot is a scholar working on Oncology, Immunology and Biological Psychiatry, having authored 55 papers that have together received 629 indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (18 papers), Colorectal Cancer Treatments and Studies (16 papers), Cancer Immunotherapy and Biomarkers (13 papers), Cutaneous Melanoma Detection and Management (9 papers), Cancer Treatment and Pharmacology (8 papers), CAR-T cell therapy research (7 papers), Immunotherapy and Immune Responses (6 papers) and Gastric Cancer Management and Outcomes (5 papers). The work is most often cited by research in Oncology (330 citations), Immunology (113 citations) and Hepatology (41 citations). Jan Willem de Groot has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Christian U. Blank, Martijn H. den Brok, I. Jolanda M. de Vries, Rutger H.T. Koornstra, Niven Mehra, Sandra van Wilpe, Winald R. Gerritsen, Willem Den Otter, Geke A.P. Hospers and R.A. De Weger. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact